Lilly rises after Viking reports maintenance-dosing weight-loss preservation
Lilly shares rose 0.8% to $1,174.37 Tuesday after Viking Therapeutics reported maintenance-dosing results for VK2735, with patients preserving up to 97% of prior weight loss.
Eli Lilly NYSE:LLY, the obesity and diabetes drug leader, faced a new competitive development after Viking Therapeutics released maintenance-dosing results for VK2735. 37 Tuesday. Viking said patients preserved as much as 97% of their prior weight loss with…